LONDON--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced a new enterprise agreement with Bioforum, a ...
BOSTON, Jan. 30, 2023 /PRNewswire/ -- Bioforum The Data Masters, a leading global Clinical Research Organization (CRO) focused on data solutions for the pharmaceutical and biotech industries, is ...
PhaseV's Trial Optimizer applies AI/ML to simulate and compare millions of trial configurations in minutes, allowing sponsors to identify the most efficient design before the first patient is enrolled ...
PhaseV, a developer of advanced AI/machine learning (ML) solutions to optimise clinical development, has entered into a strategic partnership with Bioforum to enhance the efficiency of clinical trials ...
Bioforum is expanding its leadership team, appointing Michael Goedde as the CRO's new president, according to a March 19 announcement. “As we expand our presence in North America and around the world, ...
Medidata announced a new enterprise agreement with Bioforum. The expanded partnership provides Bioforum’s biotech customers with broader access to Medidata’s AI-powered technology, enabling a more ...
Clinical software developer PhaseV is teaming up with another global CRO, unveiling a plan to infuse its trial design platform into Bioforum’s services. PhaseV’s Trial Optimizer uses machine learning ...
BEACHWOOD, Ohio — The business development center at the Beachwood Chamber of Commerce has attracted another company from Israel: BioForum Applied Knowledge Center. BioForum provides continuing ...
NESS ZIONA, Israel, April 24, 2024 /PRNewswire/ -- Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global ...
Expanded collaboration leverages Clinical Data Studio and AI-driven biometrics to deliver high-quality, efficient data services for Bioforum’s clients LONDON, November 12, 2024--(BUSINESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results